AASS
Alpha-aminoadipic semialdehyde synthase, mitochondrial
Protein Summary
Bifunctional enzyme that catalyzes the first two steps in lysine degradation. The N-terminal and the C-terminal contain lysine-ketoglutarate reductase and saccharopine dehydrogenase activity, respectively. This gene encodes a bifunctional enzyme that catalyzes the first two steps in the mammalian lysine degradation pathway. The N-terminal and the C-terminal portions of this enzyme contain lysine-ketoglutarate reductase and saccharopine dehydrogenase activity, respectively, resulting in the conversion of lysine to alpha-aminoadipic semialdehyde. Mutations in this gene are associated with familial hyperlysinemia. [provided by RefSeq, Jul 2008]
- ENST00000393376
- ENSP00000377040
- ENSG00000008311
- ENST00000417368
- ENSP00000403768
- LKRSDH
- LORSDH
- LKR/SDH
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
transcription factor perturbation | 0.91 | ||
disease perturbation | 0.83 | ||
PubMedID | 0.83 | ||
kinase perturbation | 0.71 | ||
histone modification site profile | 0.7 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 37.19 (req: < 5)
Gene RIFs: 6 (req: <= 3)
Antibodies: 189 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 37.19 (req: >= 5)
Gene RIFs: 6 (req: > 3)
Antibodies: 189 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 7
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0